ARA-290

ARA-290 Peptide Vials

ARA-290

• CAS Number: 1208243-50-8
• Molar Mass: 1257.31 g·mol⁻¹
• Chemical Formula: C₅₁H₈₄N₁₆O₂₁
• IUPAC Name: (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid

Introduction

ARA-290 Vials are an advanced research product designed solely for scientific investigations. These vials are strictly intended for research purposes and contain ARA-290, a promising peptide with potential applications in various fields of medical research.

Key Characteristics

ARA-290 is a synthetic peptide derived from erythropoietin (EPO), a hormone responsible for regulating red blood cell production. ARA-290 exhibits unique anti-inflammatory and tissue-protective properties, making it a focal point in diverse research studies.

Research Applications

ARA-290 Vials are valuable tools for studying a range of medical conditions and biological processes. Researchers can study its effects on chronic diseases, tissue repair mechanisms, and autoimmune disorders.

Research Benefits

ARA-290 and Chronic Diabetes

One notable research application of ARA-290 involves its potential impact on chronic diabetes. Studies suggest that ARA-290 may modulate inflammatory responses in diabetes, potentially serving as a basis for therapeutic interventions.

ARA-290 and Tissue Repair

ARA-290 has shown promising results in promoting tissue repair. Research studies indicate its ability to enhance tissue regeneration and reduce inflammation, potentially contributing to novel approaches in regenerative medicine.

ARA-290 and Autoimmune Disorders

Researchers are exploring the potential of ARA-290 in addressing autoimmune disorders. Preliminary studies indicate that ARA-290 may modulate immune responses, opening possibilities for future research on autoimmune conditions.

Disclaimer

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction is our top priority. If you are dissatisfied with the received product, please contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE:

All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.

References

1. Schmidt, R. E., Feng, D., Wang, Q., Green, K. G., Snipes, L. L., Yamin, M., & Brines, M. (2011). Effect of insulin and an erythropoietin-derived peptide (ARA-290) on established neuritic dystrophy and neuronopathy in Akita (Ins2 Akita) diabetic mouse sympathetic ganglia. Experimental Neurology, 232(2), 126-135. doi: 10.1016/j.expneurol.2011.05.025. PMID: 21872588; PMCID: PMC3202026. [Read More]

2. Huang, B., Jiang, J., Luo, B., Zhu, W., Liu, Y., Wang, Z., & Zhang, Z. (2018). Non-erythropoietic erythropoietin-derived peptide protects mice from systemic lupus erythematosus. Journal of Cellular and Molecular Medicine, 22(7), 3330-3339. doi: 10.1111/jcmm.13608. PMID: 29570934; PMCID: PMC6010693. [Read More]

3. Nairz, M., Haschka, D., Dichtl, S., et al. (2017). Cibinetide, a variant of ARA-290, dampens innate immune cell functions, thus ameliorating the course of experimental colitis. Scientific Reports, 7, 13012. [Read More]